Some government officials have been eyeing a ban on pay-to-delay settlements, which are designed to keep lower-cost generic drugs off the market for extended periods.   Could this be the final straw?

A major medical device maker issues a pre-emptive strike against the excise tax - is this the start of a disturbing trend?

Merck is in marketing hot water again. The Wall Street Journal reports Merck has been subpoenaed regarding the marketing of several of its drugs.

Find out which 2 companies will jointly develop and sell up to five psychiatric and neuroscience drugs in a deal that could reap billions in profits.

All this and more on this week's edition of BeakerBeat.